Table 1 Sedative drug use and mechanical ventilation treatment of participants.

From: A competing risk model analysis of dexmedetomidine of in-hospital mortality in subarachnoid hemorrhage patients

 

Group

Survival (n = 409)

Death (n = 118)

P-value

Propofol, n (%)

No

174 (42.543)

42 (35.593)

0.176

Yes

235 (57.457)

76 (64.407)

 

Midazolam, n (%)

No

228 (55.746)

58 (49.153)

0.205

Yes

181 (44.254)

60 (50.847)

 

Dexmedetomidine, n (%)

No

195 (47.677)

84 (71.186)

< 0.001

Yes

214 (52.323)

34 (28.814)

 

Pro + Mida, n (%)

No

392 (95.844)

106 (89.831)

0.012

Yes

17 (4.156)

12 (10.169)

 

Pro + Dex, n (%)

No

317 (77.506)

101 (85.593)

0.056

Yes

92 (22.494)

17 (14.407)

 

Mida + Dex

No

373 (91.198)

115 (97.458)

0.022

Yes

36 (8.802)

3 (2.542)

 

Pro + Mida + Dex, n (%)

No

371 (90.709)

108 (91.525)

0.786

Yes

38 (9.291)

10 (8.475)

 

Mechanical ventilation, n (%)

No

17 (4.156)

6 (5.085)

0.664

Yes

392 (95.844)

112 (94.915)

 
  1. Dex Dexmedetomidine, Mida Midazolam, Pro Propofol.